# Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

Source: https://onco.cc/trials/nct02798406/  
OnCo record `nct02798406` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of DNX-2401 run by DNAtrix, Inc., completed.

## Summary

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects is a phase 2 interventional study registered as NCT02798406 by DNAtrix, Inc., with 49 participants enrolled, started 2016-10-06. Conditions recorded: Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma, Gliosarcoma, Malignant Brain Tumor, Neoplasm, Neuroepithelial, Neuroectodermal Tumors, Neoplasm by Histologic Type, Neoplasm, Nerve Tissue and Nervous System Diseases. Interventions recorded: DNX-2401 and pembrolizumab.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02798406
- Phase: 2
- Setting: A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
- Sponsor: DNAtrix, Inc.
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT02798406: https://clinicaltrials.gov/study/NCT02798406

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [DNX-2401](https://onco.cc/drugs/dnx-2401/)
- companies: [DNAtrix](https://onco.cc/companies/dnatrix/)

---
JSON: https://onco.cc/api/v1/entities/nct02798406.json